Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat, Anwesha Chaudhury, Nadia Solovieff, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 13, pp. 1458-1467
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Triple negative breast cancer: Pitfalls and progress
Paola Zagami, Lisa A. Carey
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 349
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Elisa Agostinetto, Mattia Rediti, Danai Fimereli, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2824-2824
Open Access | Times Cited: 184
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Yen‐Shen Lu, Seock‐Ah Im, Marco Colleoni, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 5, pp. 851-859
Open Access | Times Cited: 172
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2796-2811
Open Access | Times Cited: 131
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Elisa Agostinetto, Joseph Gligorov, Martine Piccart
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 763-774
Open Access | Times Cited: 84
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Fátima Cardoso, Shani Paluch‐Shimon, Eva Schumacher-Wulf, et al.
The Breast (2024) Vol. 76, pp. 103756-103756
Open Access | Times Cited: 38
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial
S W M Lammers, Sandra M. E. Geurts, Karlijn Susanna Francisca Maria Hermans, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104154-104154
Open Access | Times Cited: 3
Clinical Implications of Breast Cancer Intrinsic Subtypes
Alejandro Ríos-Hoyo, Naing-Lin Shan, Philipp L Karn, et al.
Advances in experimental medicine and biology (2025), pp. 435-448
Closed Access | Times Cited: 2
Dissecting the biological heterogeneity of HER2-positive breast cancer
Francesco Schettini, Aleix Prat
The Breast (2021) Vol. 59, pp. 339-350
Open Access | Times Cited: 89
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma Asghar, Ruhi Kanani, Rebecca Roylance, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 66
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Marta Palafox, Laia Monserrat, Meritxell Bellet, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 63
A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
Francesco Schettini, Fara Brasó‐Maristany, Nicole M. Kuderer, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 46
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
Claudette Falato, Francesco Schettini, Tomás Pascual, et al.
Cancer Treatment Reviews (2022) Vol. 112, pp. 102496-102496
Open Access | Times Cited: 41
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat, Fara Brasó‐Maristany, Olga Martínez‐Sáez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
CCNE1andPLK1Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Ángel Guerrero‐Zotano, Stefania Belli, Christoph Zielinski, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 8, pp. 1557-1568
Open Access | Times Cited: 28
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Yeon Hee Park, Seock‐Ah Im, Kyunghee Park, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 28
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
Ciara C. O’Sullivan, Robert Clarke, Matthew P. Goetz, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 26
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis
Deniz Can Güven, Taha Koray Şahin
Breast Cancer Research and Treatment (2024) Vol. 204, Iss. 3, pp. 443-452
Open Access | Times Cited: 11
Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer
Michele Bottosso, F. Mosele, Stefan Michiels, et al.
ESMO Open (2024) Vol. 9, Iss. 3, pp. 102247-102247
Open Access | Times Cited: 9
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Kelvin K H Bao, Leone Sutanto, Shirley S. W. Tse, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133132-e2133132
Open Access | Times Cited: 43
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
Francesca Carlino, Anna Diana, Anna Ventriglia, et al.
Cancers (2022) Vol. 14, Iss. 20, pp. 4981-4981
Open Access | Times Cited: 29
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression
Ipshita Nandi, Harvey W. Smith, Virginie Sanguin‐Gendreau, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top